Conscious Versus General Anesthesia in TAVR

Patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) can safely undergo the procedure under conscious sedation.

Sedación consciente vs anestesia general en el TAVI

Conscious sedation has been adopted in clinical practice as a natural way of simplifying and conducting the procedure in the least invasive way possible.

Currently, up to 50% of patients undergo TAVR under conscious sedation, but so far there was no randomized evidence on the matter.

SOLVE-TAVI was a multicenter, open-label, 2×2 factorial, randomized trial of 447 patients with aortic stenosis undergoing TAVR, comparing conscious sedation vs. general anesthesia.

The primary efficacy endpoint was a composite powered for equivalence between both strategies for anesthesia. The composite endpoint at 30 days included: all-cause mortality, stroke, infarction, infection requiring antibiotic treatment, and acute kidney injury.


Read also: FFR and iFR Discordance in up to 20% of Cases: Which One Should Inform Our Decisions?


The primary endpoint occurred in 27.2% of patients in the conscious sedation arm vs. 26.4% of patients in the general anesthesia arm (p for equivalence = 0.015).

The rates of individual components also reached significance for equivalence. All-cause mortality was 3.2% for conscious sedation vs. 2.3% for general anesthesia; as regards stroke, 2.4% vs. 2.8%; infarction, 0.5% vs. 0%; infection requiring antibiotic treatment, 21.1% vs. 22%, and acute kidney injury, 9% vs. 9.2%, respectively.

There was a lower need for inotropes or vasopressors in patients who received conscious sedation (62.8% vs. 97.3%).

Conclusion

Conscious sedation had similar results in patients with severe aortic stenosis undergoing transfemoral TAVR compared with general anesthesia. These findings suggest that conscious sedation may be used safely during the procedure.

10-1161-circulationaha-120-046451

Original Title: General versus Local Anesthesia with Conscious Sedation in Transcatheter Aortic Valve Implantation: The Randomized SOLVE-TAVI Trial.

Reference: Holger Thiele et al. Circulation. 2020 Oct 13;142(15):1437-1447. doi: 10.1161/CIRCULATIONAHA.120.046451.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...